Since we know that up to 80% of those with clinical DFH will carry an FH-causing mutation [13,14] while probably 80% of those with clinical PFH have a polygenic aetiology of their hyperlipidaemia [15,16], this confirms reports that carriage of an FH mutation is associated with greater CHD risk [4]. The gene discussed is FH; the disease is hyperlipidemia.